Effective April 1, 2024, the following FDA-approved adalimumab biosimilars will be added to the Tufts Health RITogether pharmacy formulary at preferred status with prior authorization:
- Adalimumab-adbm
- Adalimumab-fkjp
- Hadlima
All other available FDA-approved adalimumab biosimilars and the reference product Humira (adalimumab) will be non-preferred products and non-covered effective April 1, 2024.